Fibromyalgia Treatments Market Research Report: Information by Treatment (Antidepressants, Antiepileptic, Muscle Relaxants, And Others), By End User (Hospital and Clinic), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Fibromyalgia Treatment Market, by Diagnosis

6.1 Introduction

6.2 Laboratory Evaluation

6.2.1 Market Estimates & Forecast, 2017–2023

6.3 Presence of Central Sensitization

6.3.1 Market Estimates & Forecast, 2017–2023

Chapter 7. Global Fibromyalgia Treatment Market, by Treatment

7.1 Introduction

7.2 Symptomatic Treatment

7.2.1 Market Estimates & Forecast, 2017–2023

7.3 Targeted Treatment

7.3.1 Market Estimates & Forecast, 2017–2023

Chapter 8. Global Fibromyalgia Treatment Market, by End-User

8.1 Introduction

8.2 Hospital

8.2.1 Market Estimates & Forecast, 2017–2023

8.3 Clinics

8.3.2 Market Estimates & Forecast, 2017–2023

8.4 Diagnostic Centers

8.4.1 Market Estimates & Forecast, 2017–2023

8.5 Others

8.5.2 Market Estimates & Forecast, 2017–2023

Chapter 9. Global Fibromyalgia Treatment Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 U.S.

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 U.K.

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Pfizer

11.1.1 Company Overview

11.1.2 Types Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 GlaxoSmithKline

11.2.1 Company Overview

11.2.2 Types Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 AstraZeneca

11.3.1 Company Overview

11.3.2 Types Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 F. Hoffmann-La Roche AG

11.4.1 Company Overview

11.4.2 Types/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Astellas Pharma

11.5.1 Company Overview

11.5.2 Types Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 Johnson & Johnson Services, Inc.

11.6.1 Company Overview

11.6.2 Types Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 SANOFI

11.7.1 Overview

11.7.2 Types Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Fibromyalgia Treatment industry

Chapter 13 Appendix

LIST OF TABLES

Table 1 Fibromyalgia Treatment Industry Synopsis, 2017–2023

Table 2 Fibromyalgia Treatment Market Estimates and Forecast, 2017–2023, (USD Million)

Table 3 Fibromyalgia Treatment Market, by Region, 2017–2023, (USD Million)

Table 4 Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 5 Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 6 Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)

Table 7 North America Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 8 North America Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 9 North America Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)

Table 10 US Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 11 US Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 12 US Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)

Table 13 Canada Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 14 Canada Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 15 Canada Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)

Table 16 South America Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 17 South America Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 18 South America Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)

Table 19 Europe Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 20 Europe Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 21 Europe Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)

Table 22 Western Europe Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 23 Western Europe Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 24 Western Europe Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)

Table 25 Eastern Europe Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 26 Eastern Europe Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 27 Eastern Europe Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)

Table 28 Asia Pacific Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 29 Asia Pacific Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 30 Asia Pacific Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)

Table 31 Middle East & Africa Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 32 Middle East & Africa Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 33 Middle East & Africa Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Fibromyalgia Treatment Market

Figure 3 Segmentation Market Dynamics for Fibromyalgia Treatment Market

Figure 4 Global Fibromyalgia Treatment Market Share, by Diagnosis, 2016

Figure 5 Global Fibromyalgia Treatment Market Share, by Treatment, 2016

Figure 6 Global Fibromyalgia Treatment Market Share, by End-User, 2016

Figure 7 Global Fibromyalgia Treatment Market Share, by Region, 2016

Figure 8 North America Fibromyalgia Treatment Market Share, by Country, 2016

Figure 9 Europe Fibromyalgia Treatment Market Share, by Country, 2016

Figure 10 Asia Pacific Fibromyalgia Treatment Market Share, by Country, 2016

Figure 11 Middle East & Africa Fibromyalgia Treatment Market Share, by Country, 2016

Figure 12 Global Fibromyalgia Treatment Market: Company Share Analysis, 2016 (%)

Figure 13 Pfizer: Key Financials

Figure 14 Pfizer Segmental Revenue

Figure 15 Pfizer: Geographical Revenue

Figure 16 GlaxoSmithKline: Key Financials

Figure 17 GlaxoSmithKline: Segmental Revenue

Figure 18 GlaxoSmithKline: Geographical Revenue

Figure 19 AstraZeneca: Key Financials

Figure 20 AstraZeneca: Segmental Revenue

Figure 21 AstraZeneca: Geographical Revenue

Figure 22 F. Hoffmann-La Roche AG: Key Financials

Figure 23 F. Hoffmann-La Roche AG: Segmental Revenue

Figure 24 F. Hoffmann-La Roche AG: Geographical Revenue

Figure 25 Astellas Pharma: Key Financials

Figure 26 Astellas Pharma: Segmental Revenue

Figure 27 Astellas Pharma Geographical Revenue

Figure 28 Johnson & Johnson Services, Inc.: Key Financials

Figure 29 Johnson & Johnson Services, Inc.: Segmental Revenue

Figure 30 Johnson & Johnson Services, Inc.: Geographical Revenue

Figure 31 SANOFI: Key Financials

Figure 32 SANOFI: Segmental Revenue

Figure 33 SANOFI: Geographical Revenue